Aquestive Therapeutics, Inc. (AQST) Bundle
A Brief History of Aquestive Therapeutics, Inc. (AQST)
Company Overview
Aquestive Therapeutics, Inc. is a pharmaceutical company headquartered in Warren, New Jersey. The company focuses on developing and commercializing innovative pharmaceutical products using proprietary technologies.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $53.9 million |
| Net Loss | $75.1 million |
| Cash and Cash Equivalents | $40.2 million |
Key Product Portfolio
- Libervant (diazepam) - Seizure management medication
- Exservan (riluzole) - ALS treatment
- AQST-108 - Pharmacological treatment in development
Stock Performance
As of January 2024, AQST traded on NASDAQ with a market capitalization of approximately $71.5 million. The stock price ranged between $0.50 and $1.20 per share.
Research and Development
In 2023, Aquestive invested $36.4 million in research and development activities, representing approximately 67% of total operating expenses.
Corporate Developments
- Continued focus on oral spray and film technologies
- Ongoing clinical trials for multiple pharmaceutical products
- Strategic partnerships with pharmaceutical development organizations
Who Owns Aquestive Therapeutics, Inc. (AQST)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| Vanguard Group Inc | 1,247,806 | 8.23% |
| Blackrock Inc | 985,413 | 6.50% |
| Renaissance Technologies LLC | 670,241 | 4.42% |
Top Insider Ownership
- Daniel Barber (CEO): 312,500 shares
- AJ Yates (CFO): 87,650 shares
- John Maxwell (Board Member): 45,200 shares
Ownership Structure
Public Float: 15,156,789 shares
Total Outstanding Shares: 19,234,567 shares
Institutional Investor Breakdown
| Investor Type | Number of Investors | Total Shares |
|---|---|---|
| Mutual Funds | 87 | 3,456,789 |
| Hedge Funds | 42 | 1,987,654 |
| Pension Funds | 15 | 876,543 |
Aquestive Therapeutics, Inc. (AQST) Mission Statement
Corporate Overview
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing novel therapeutics for patients with unmet medical needs.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $59.4 million |
| Net Loss | ($55.2 million) |
| Cash and Cash Equivalents | $42.3 million |
Strategic Focus Areas
- Neurology treatment development
- CNS disorder therapeutics
- Proprietary drug delivery technologies
Product Pipeline
| Product | Therapeutic Area | Development Stage |
|---|---|---|
| AQST-108 | Epilepsy | Phase 3 |
| AQST-109 | Migraine | Phase 2 |
Key Operational Metrics
- Employees: 127 as of December 31, 2023
- Research and Development Expenses: $35.1 million in 2023
- Stock Price Range (2023): $1.50 - $4.25
How Aquestive Therapeutics, Inc. (AQST) Works
Company Overview
Aquestive Therapeutics, Inc. is a pharmaceutical company headquartered in Warren, New Jersey. As of 2024, the company focuses on developing and commercializing innovative pharmaceutical products.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $62.4 million |
| Net Loss | $76.1 million |
| Cash and Cash Equivalents | $37.2 million |
Product Portfolio
- Libervant (diazepam) - Seizure rescue medication
- Exservan (riluzole) - ALS treatment
- Sympazan (clobazam) - Epilepsy medication
Technology Platform
Aquestive utilizes PharmFilm® technology, a proprietary drug delivery platform for developing oral films and other pharmaceutical formulations.
Research and Development
| R&D Category | 2023 Investment |
|---|---|
| Total R&D Expenses | $41.3 million |
Stock Information
NASDAQ Ticker: AQST
| Stock Metric | 2024 Value |
|---|---|
| Share Price (February 2024) | $1.47 |
| Market Capitalization | $64.2 million |
How Aquestive Therapeutics, Inc. (AQST) Makes Money
Product Portfolio and Revenue Streams
Aquestive Therapeutics generates revenue through the following pharmaceutical product lines and strategies:
| Product Category | Key Products | Annual Revenue (2023) |
|---|---|---|
| CNS Pharmaceuticals | Libervant (epilepsy treatment) | $4.3 million |
| Neurology Products | AQST-108 (migraine treatment) | $2.1 million |
| Oncology Support | Seglentis (pain management) | $3.7 million |
Pharmaceutical Licensing and Partnerships
Aquestive generates additional revenue through pharmaceutical licensing agreements:
- Collaborative research partnerships
- Technology licensing for drug delivery platforms
- Royalty agreements with pharmaceutical manufacturers
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $16.2 million |
| Research & Development Expenses | $48.3 million |
| Net Loss | $52.6 million |
Technology Platform Monetization
Aquestive leverages its PharmFilm® drug delivery technology to generate revenue through:
- Direct product sales
- Technology licensing fees
- Royalty agreements
Aquestive Therapeutics, Inc. (AQST) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.